Web-based Health Education on Information, Motivation, Behavioral Skills Related to Human Papilloma Virus Vaccination (HPV Vaccine)

September 28, 2026 updated by: Nehmedo Ezzat osman, Mansoura University

Effect of Web-based Health Education on Information, Motivation, Behavioral Skills Related to Human Papilloma Virus Vaccination Among Female University Students

This study aims to evaluate the effect of web-based health education on information, motivation, behavioral skills related to human papilloma virus vaccination among female University students Research hypothesis

  • Female University students who receive web based education are expected to improve information about human papilloma virus vaccination more than control group.
  • Female University students who receive web based education are expected to exhibit greater motivation compared with the control group.
  • Female University students who receive web based education are expected to demonstrate greater behavioral skills compared with the control group.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

In Egypt, cervical cancer is the 13th most prevalent cancer among women and the 9th most common cancer among women aged 15 to 44 years . In 2020, an estimated 1,320 new cases and 744 deaths due to cervical cancer were reported. A national screening program conducted in 2002 assessed the prevalence and risk factors of pre-invasive and invasive cervical cancer among 5,453 women aged 35 to 60 years, revealing prevalence rates of 0.5% for pre-invasive high-grade lesions and 0.04% for invasive cervical cancer . Currently, Egypt does not have a structured nationwide cervical cancer screening program; screening largely depends on women's perceptions and their healthcare providers' recommendations. Evidence indicates that healthcare provider recommendations are a critical factor in promoting screening adherence. Recently, Egypt has launched initiatives in selected governorates to raise awareness about early detection and HPV vaccination. However, the knowledge, attitudes, and practices of Egyptian women regarding cervical cancer screening at the national level remain largely unknown .

Improving information, motivation, and behavioral skills related to HPV vaccination among university students addresses this critical public health gap. By targeting future nurses, this study aims to enhance preventive health practices and contribute to reducing HPV-related infections and cervical cancer incidence. Nursing students play a pivotal role in health promotion and disease prevention. Strengthening their information, motivation, and behavioral skills equips them to educate peers, patients, and the broader community about HPV infection and vaccination. By empowering nurses with evidence-based knowledge and practical skills, this study supports the development of a workforce capable of positively influencing vaccination behaviors and public health outcomes.

The use of web-based education, guided by the Information-Motivation-Behavioral Skills (IMB) model, offers a flexible, cost-effective, and accessible approach to learning. Web-based interventions can reach large groups efficiently, provide tailored content, and facilitate skill-building in diverse populations. The findings from this study can guide health policy, and shape future educational strategies to improve HPV vaccine coverage and preventive health behaviors among young adults.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
340

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Nehmedo Ezzat Osman, Assisstant professor
  • Phone Number: 01011301978
  • Email: nehmedo@mans.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 22 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • - Females 18 years of age and more.
  • first-year undergraduates
  • No vaccination contraindications.
  • Female undergraduate university students from different faculties.
  • Can use a digital device (smartphone, personal computer, laptop, or tablet).
  • An active email address is required, as all reminders will be sent via email.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Non-HPV popular science content

Non-HPV popular science content
Behavioral: Web-based IMB education delivered as daily modules

Web-based IMB education delivered as daily modules

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Tool II: information, motivation, and behavioral skills regarding HPV vaccination adopted from (wang et al.,2023) to assess information, motivation, and behavioral skills of students regarding HPV vaccination includes three parts. Part one: female unive
Time Frame: immediately and after 3 months

Tool II: information, motivation, and behavioral skills regarding HPV vaccination adopted from (wang et al.,2023) to assess information, motivation, and behavioral skills of students regarding HPV vaccination includes three parts. Part one: female university students' information concerning human papillomavirus consist of 11 item such as: HPV is related to the development of cervical cancer, HPV is almost asymptomatic HPV is very common , etc Scoring system: the answers were "Agree," "Disagree," or "I do not know. Each correct answer scored 1 point, while incorrect or unknown answers scored 0 points. The total score of the information questions was derived by adding the number of correct responses. The higher score indicate better information.

Part II: Female university students Motivation for vaccination: It includes 5 dimensions with a total of 19 items: perceived susceptibility (2 items), perceived severity (4 items), perceived benefits (3 items) and barriers (5 items), and sub
immediately and after 3 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Web-based platform evaluation form:including four domains: accessibility and usability, functionality and content quality, technical support and reliability and user satisfaction. Scoring system: answer for these items will be measure on 3- point Likert
Time Frame: immediately after intervention

Tool III: Web-based platform evaluation form:

It was developed by researcher to assess female university students' feedback about the web-based platform including four domains: accessibility and usability, functionality and content quality, technical support and reliability and user satisfaction.
immediately after intervention
Web-based platform evaluation form:including four domains: accessibility and usability, functionality and content quality, technical support and reliability and user satisfaction. Scoring system: answer for these items will be measure on 3- point Likert
Time Frame: immediately after intervention
immediately after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Mansoura University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 22, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 28, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 5, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 28, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 0857

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings